Glycerin

Glycerin

SCHEMBL253986

ClCC1CO1.OCC(O)CO

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
TDP1 Q9NUW8 1/20 0.62
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL5226146 0.94 ALDH1A1 (0.54) ALDH1A1TDP1LMNA
SCHEMBL28141452 0.87 ALDH1A1 (0.52) ALDH1A1TDP1LMNA
SCHEMBL1830406 0.86 ALDH1A1 (0.50) ALDH1A1TDP1
SCHEMBL8563124 0.83 ALDH1A1 (0.65) ALDH1A1TDP1
Sorbitol SCHEMBL1830742 0.82 TDP1 (0.56) ALDH1A1TDP1LMNA
Isopropyl Alcohol SCHEMBL18894306 0.80
Glycerin SCHEMBL10788232 0.80 ALDH1A1 (0.47) ALDH1A1TDP1LMNATHRB
Ethylene Glycol SCHEMBL8467093 0.79
Hydrogen Peroxide SCHEMBL28159702 0.79
SCHEMBL118159 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5077167-A Encapsulated toner compositions XEROX CORPORATION (US) 1991-12-31 US claimed
US-20260117190-A1 METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2026-04-30 US disclosed
US-20260115694-A1 Single-atom Nanozymes, Preparation and Applications thereof UNIV CITY HONG KONG (HK) 2026-04-30 US disclosed
US-12613238-B2 Diagnostic and prognostic utility of exosomes in immunotherapy BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-04-28 US disclosed
US-20260033484-A1 CROSS-CIRCULATION PLATFORM FOR RECOVERY, REGENERATION, AND MAINTENANCE OF EXTRACORPOREAL ORGANS UNIV COLUMBIA (US) 2026-02-05 US disclosed
EP-4685158-A1 FIBRILLARY APOLIPOPROTEIN E (APOE) FOR USE IN A METHOD OF TREATMENT AND/OR PREVENTION OF A NEURODEGENERATIVE DISEASE Technische Universität München (DE) 2026-01-28 EP disclosed
US-20250388761-A1 HYBRID ORGANIC-INORGANIC TWO-DIMENSIONAL METAL CARBIDE MXENES UNIV CHICAGO (US) 2025-12-25 US disclosed
US-20250352562-A1 PREVENTION OF SYMPATHETIC DENERVATION OF THE PINEAL GLAND IN CARDIAC DISEASE UNIV MUENCHEN TECH (DE) 2025-11-20 US disclosed
US-12446572-B2 Cross-circulation platform for recovery, regeneration, and maintenance of extracorporeal organs THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-10-21 US disclosed
WO-2025217271-A1 CRYO-EM STRUCTURE OF THE BRINE SHRIMP ATP SYNTHASE AND AN INACTIVATION MECHANISM OF ATP SYNTHASE LEAK CHANNEL FOR USE IN THERAPEUTIC APPROACHES THE PENN STATE RESEARCH FOUNDATION (US) 2025-10-16 WO disclosed
US-4436909-A HAIR COSMETICS L'OREAL (FR) 1984-03-13 US disclosed
US-4397985-A GAMMA-GLYCIDOXYPROPYLTRIMETHOXYSILANE ALLIED CORPORATION (US) 1983-08-09 US disclosed
US-4389456-A YARNS, LUBRICANTS, OXIDATION RESISTANCE ALLIED CORPORATION (US) 1983-06-21 US disclosed
EP-0079443-A2 Stabilized finish composition ALLIED CORPORATION (US) 1983-05-25 EP disclosed
US-4220602-A FOR HAIR COSMETICS L'OREAL (FR) 1980-09-02 US disclosed
US-4133783-A Thermosetting cellulose ester powder coating composition EASTMAN KODAK COMPANY (US) 1979-01-09 US disclosed
US-4096332-A POLYHYDROXYLATED TERTIARY AMINES OR QUATERNARY AMMONIUM SALTS THEREOF L'OREAL (FR) 1978-06-20 US disclosed
US-4009255-A POLYHYDROXYLATED TERTIARY AMINES SOCIETE ANONYME DITE: L'OREAL (FR) 1977-02-22 US disclosed
US-4001141-A POLYETHERS SOCIETE ANONYME DIT: L'OREAL (FR) 1977-01-04 US disclosed
US-3954882-A Non-ionic surface-active agents derived from fatty chain diols L'OREAL (FR) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12613238-B2 Diagnostic and prognostic utility of exosomes in immunotherapy CD274, ICOS, PDCD1 ALDH1A1 2974/4885TDP1 2962/4885LMNA 4712/4885
US-20260033484-A1 CROSS-CIRCULATION PLATFORM FOR RECOVERY, REGENERATION, AND MAINTENANCE OF EXTRACORPOREAL ORGANS VEGFA, PROX1, CFTR ALDH1A1 3201/4885TDP1 3577/4885LMNA 4324/4885
US-20260117190-A1 METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION ALPG, NOTCH3, PAX3 ALDH1A1 4225/4885TDP1 4606/4885LMNA 2144/4885
US-20260115694-A1 Single-atom Nanozymes, Preparation and Applications thereof CA7, CA2, CA6 ALDH1A1 3086/4885TDP1 3992/4885LMNA 2458/4885
US-20250388761-A1 HYBRID ORGANIC-INORGANIC TWO-DIMENSIONAL METAL CARBIDE MXENES AXIN2, H1-2, NXF1 ALDH1A1 921/4885TDP1 2454/4885LMNA 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.